Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 7, 2020
Previous Article Next Article

A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

Author affiliations

Abstract

We evaluate the application of surfactant-free liquid-phase exfoliated MoS2 nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody–antigen based recognition element. Employing antigen–antibody binding, we increased the probability of the endocytosis of MoS2 nanosheets into CAIX expressing cells by 30%. The nanosheets are functionalized with a specific antibody M75, which forms an antigen–antibody complex with CAIX. The bioconjugation of MoS2 nanosheets involves biocompatible components with low cytotoxicity, verified in the tested cell lines by fluorescence-based cell viability assay. The cellular internalization is quantified by flow cytometry, while the internalization is confirmed by label-free confocal Raman imaging. Raman measurements show increased lysosomal activity in the proximity of the internalized nanoplatforms.

Graphical abstract: A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

Back to tab navigation

Supplementary files

Article information


Submitted
09 Dec 2019
Accepted
07 Feb 2020
First published
17 Feb 2020

Biomater. Sci., 2020,8, 1973-1980
Article type
Paper

A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

A. Kálosi, M. Labudová, A. Annušová, M. Benkovičová, M. Bodík, J. Kollár, M. Kotlár, P. Kasak, M. Jergel, S. Pastoreková, P. Siffalovic and E. Majkova, Biomater. Sci., 2020, 8, 1973
DOI: 10.1039/C9BM01975H

Social activity

Search articles by author

Spotlight

Advertisements